...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Laryngoscope: A Medical Journal for Clinical and Research Contributions in Otolaryngology, Head and Neck Medicine and Surgery, Facial Plastic and Reconstructive Surgery .. >Neutron Therapy for High-Grade Salivary Carcinomas in the Adjuvant and Primary Treatment Setting
【24h】

Neutron Therapy for High-Grade Salivary Carcinomas in the Adjuvant and Primary Treatment Setting

机译：中子疗法在佐剂和初级治疗环境中进行高级唾液癌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives/Hypothesis Our primary objective was to compare differences in survival of patients with high-grade salivary gland carcinomas (SGCs) receiving adjuvant neutron versus photon radiotherapy using a hospital-based national cohort and restricted mean survival time (RMST) analysis. Our secondary objective was to compare survival of similar patients treated with primary neutron versus photon radiation. Study Design Multicenter, retrospective population-based study of patients within the National Cancer Database from 2004 to 2014. Methods One thousand eight hundred forty-four patients were selected on diagnosis of high-grade parotid and submandibular malignancies. One thousand seven hundred seventy-seven patients receiving photon and 67 patients receiving neutron therapy were identified who met inclusion criteria. Patients were then categorized as having primary surgery with adjuvant radiation or primary radiation without prior surgery. Bivariate analysis was performed to assess for differences between groups, and RMST analysis was performed at 1-, 2-, and 5-year timepoints with controlling for available covariate data. Results There was no significant difference in RMST for patients receiving neutrons over photons at 1, 2, and 5 years in the adjuvant setting. Among patients undergoing primary radiotherapy, there was a difference in RMST of 2.29 months at 1 year and 5.05 months at 2 years for neutrons over photons, though this benefit was not observed at 5 years post-therapy. Conclusions For patients with high grade SGCs undergoing adjuvant photon versus neutron radiotherapy, there was no difference in RMST. There was observed to be a significant difference in RMST at 1 and 2 years among patients undergoing primary neutron therapy of up to 5 months. Given the benefit observed with primary neutron therapy, it should be considered in both the primary and adjuvant treatment setting. Level of Evidence 4Laryngoscope, 2020
机译：目的/假设我们的主要目的是使用基于医院的全国队列和限制性平均生存时间（RMST）分析，比较接受辅助中子与光子放疗的高级别涎腺癌（SGC）患者的生存率差异。我们的第二个目标是比较接受初级中子和光子辐射治疗的类似患者的生存率。研究设计2004年至2014年国家癌症数据库中基于人群的多中心回顾性研究。方法选择1844例腮腺及颌下腺恶性肿瘤患者。1777名接受光子治疗的患者和67名接受中子治疗的患者符合纳入标准。然后将患者分为接受辅助放疗的一期手术和未经手术的一期放疗。进行双变量分析以评估各组之间的差异，在1年、2年和5年时间点进行RMST分析，并控制可用的协变量数据。结果在辅助治疗的1年、2年和5年中，接受中子多于光子治疗的患者的RMST没有显著差异。在接受初级放射治疗的患者中，中子对光子的RMST在1年时为2.29个月，在2年时为5.05个月，但在治疗后5年未观察到这种益处。结论对于接受辅助光子与中子放射治疗的高级别SGC患者，RMST没有差异。在接受长达5个月的初级中子治疗的患者中，观察到1年和2年的RMST存在显著差异。鉴于初级中子治疗所观察到的益处，在初级和辅助治疗环境中都应该考虑。证据水平4喉镜，2020年

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号